Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease.
The clinical pharmacology concerned in the evolution of deprenyl as an adjuvant in the treatment of Parkinson's disease is briefly reviewed, with an assessment of its therapeutic potential. Experiments to clarify its mode of action are described, indicating that its clinical effects do not depend upon its amphetamine metabolites.
D000661:Amphetamine / Q000652:urine; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008694:Methamphetamine / Q000652:urine; D010300:Parkinson Disease / Q000188:drug therapy* / Q000652:urine; D010627:Phenethylamines / Q000627:therapeutic use*; D012642:Selegiline / Q000627:therapeutic use*
D010627:Phenethylamines; D012642:Selegiline; D008694:Methamphetamine; D000661:Amphetamine